Physician profile
Daniel Vernier
NPI 1891868345
$506.92
in general payments reported to CMS, 2019-2025
14 companies · $373 in 2025
The $373 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.77 · 2020: $13.11 · 2023: $32.84 · 2024: $52.21 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $114.46 | 2025 | Voxzogo 1.2mg |
| Pfizer INC. | $76.26 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $54.72 | 2025 | |
| Ironshore Pharmaceuticals INC. | $47.00 | 2023-2024 | Jornay Pm |
| Kowa Pharmaceuticals America, INC. | $33.93 | 2025 | Zoryve |
| Alk-Abello, INC | $28.47 | 2025 | Neffy |
| Sanofi Pasteur INC. | $27.23 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $26.69 | 2019-2020 | |
| Genentech USA, INC. | $22.19 | 2019 | |
| Noven Therapeutics, LLC | $18.47 | 2025 | Xelstrym |
| Collegium Pharmaceutical, INC. | $18.08 | 2025 | Jornay Pm |
| Tris Pharma INC | $15.80 | 2025 | Dyanavel Xr |
| Cranial Technologies, INC | $15.38 | 2024 | Doc Band |
| Corium, LLC | $8.24 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Vernier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.